Ginkgo Bioworks (DNA) News Today

North Star Asset Management Inc. grew its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 162.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 231,100 shares of the company's stock after acquiri

Ginkgo Bioworks (NYSE:DNA) Reaches New 52-Week Low at $5.64

Pine Valley Investments Ltd Liability Co increased its holdings in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 653.7% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 220,607 shares of the

Ginkgo Bioworks (NYSE:DNA) Reaches New 1-Year Low at $7.26

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) was the recipient of a large decline in short interest in August. As of August 15th, there was short interest totalling 3,840,000 shares, a decline of 96.9% from the July 31st total of 123,460,000 shares. Based on an average daily volume of 1,500,000 shares, the days-to-cover ratio is currently 2.6 days. Approximately 10.8% of the shares of the company are short sold.

Baillie Gifford & Co. cut its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 42.3% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 134,425,866 shares of the company's stock after sell

BTIG Research upped their price target on shares of Ginkgo Bioworks from $0.20 to $7.00 and gave the company a "sell" rating in a research report on Friday.

Sumitomo Mitsui Trust Holdings Inc. cut its stake in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 95.4% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,542,002 shares of the company's stock after

Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report) have earned an average recommendation of "Reduce" from the six brokerages that are covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, two have issued a hold

Ginkgo Bioworks (NYSE:DNA) Shares Down 3.8%

Ginkgo Bioworks (NYSE:DNA) Sees Strong Trading Volume

Ginkgo Bioworks (NYSE:DNA) Hits New 1-Year Low at $8.37

Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.22

Ginkgo Bioworks (NYSE:DNA) Shares Gap Down to $0.24

Ginkgo Bioworks (NYSE:DNA) Shares Down 7.9%

Ginkgo Bioworks (NYSE:DNA) Shares Up 7.7%

Ginkgo Bioworks (NYSE:DNA) Hits New 52-Week Low at $0.25

Cetera Investment Advisers raised its position in Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 2,683.7% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,264,107 shares of the company's stock after purchasing an additional

Ginkgo Bioworks (NYSE:DNA) Shares Gap Up to $0.27

Ginkgo Bioworks (NYSE:DNA) Shares Down 4.4%

Ginkgo Bioworks (NYSE:DNA) Sets New 12-Month Low at $0.26

Vanguard Group Inc. trimmed its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 5.2% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 125,856,664 shares of the company's stock after selling 6

Ginkgo Bioworks (NYSE:DNA) Shares Gap Down to $0.37